美国住院患者多重耐药细菌感染相关医疗费用的全国估计
该研究基于美国退伍军人事务部医疗系统2007年1月至2015年10月的住院患者数据,采用回顾性队列研究和多变量广义线性模型,估计多重耐药细菌感染的归因医疗费用。
要点
- 2017年美国耐药感染合计治疗费用估计46亿美元。
核心结论
- antimicrobial-resistant infections led to substantial healthcare costs.
研究设计与样本
- 回顾性队列研究,纳入美国退伍军人事务部医疗系统2007年1月至2015年10月住院患者。
- 采用多变量广义线性模型估计归因成本,并乘以722家美国医院2017年各病原体感染数推算全国费用。
临床怎么用
- 提示多重耐药细菌感染带来显著医疗费用负担,临床应重视耐药菌感染的预防和控制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treating patients with infections due to multidrug-resistant pathogens often requires substantial healthcare resources. The purpose of this study was to report estimates of the healthcare costs associated with infections due to multidrug-resistant bacteria in the United States (US). METHODS: We performed retrospective cohort studies of patients admitted for inpatient stays in the Department of Veterans Affairs healthcare system between January 2007 and October 2015. We performed multivariable generalized linear models to estimate the attributable cost by comparing outcomes in patients with and without positive cultures for multidrug-resistant bacteria. Finally, we multiplied these pathogen-specific, per-infection attributable cost estimates by national counts of infections due to each pathogen from patients hospitalized in a cohort of 722 US hospitals from 2017 to generate estimates of the population-level healthcare costs in the US attributable to these infections. RESULTS: Our analysis cohort consisted of 16 676 patients with community-onset infections and 172 712 matched controls and 8246 patients with hospital-onset infections and 66 939 matched controls. The highest cost was seen in hospital-onset invasive infections, with attributable costs (95% confidence intervals) ranging from $30 998 ($25 272-$36 724) for methicillin-resistant Staphylococcus aureus to $74 306 ($20 377-$128 235) for carbapenem-resistant (CR) Acinetobacter. The highest attributable costs for community-onset invasive infections were seen in CR Acinetobacter ($62 396; $20 370-$104 422). Treatment of these infections cost an estimated $4.6 billion ($4.1 billion-$5.1 billion) in 2017 in the US for community- and hospital-onset infections combined. CONCLUSIONS: We found that antimicrobial-resistant infections led to substantial healthcare costs.
引用
- Nelson RE, Hatfield KM, Wolford H, et al. National Estimates of Healthcare Costs Associated With Multidrug-Resistant Bacterial Infections Among Hospitalized Patients in the United States. Clin Infect Dis. 2021. PMID: 33512523. doi:10.1093/cid/ciaa1581
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。